Uncategorized
GenSight Biologics Receives Approval to Include Teenage Patients in RESCUE and REVERSE Phase III Trials with GS010 in Leber’s Hereditary Optic Neuropathy
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Paris: SIGHT) (Euronext: SIGHT, FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that regulatory agencies and ethics committees in the United States, France and the United Kingdom, have authorized a protocol amendment to include teenage patients (15-18 years) in RESCUE and REVERSE
